Brentuximab vedotin as frontline treatment for HIV-related extracavitary primary effusion lymphoma.

Autor: Sandoval-Sus JD; Department of Malignant Hematology and Cellular Therapy at Memorial Healthcare System, H. Lee Moffitt Cancer Center, 801 N Flamingo Road, Pembroke Pines, 33028, FL, USA. jsandovalsus@mhs.net., Brahim A; Department of Pharmacy, Memorial Healthcare System, Pembroke Pines, FL, USA., Khan A; Department of Pharmacy, Memorial Healthcare System, Pembroke Pines, FL, USA., Raphael B; Department of Diagnostic Radiology, Memorial Healthcare System, Pembroke Pines, FL, USA., Ansari-Lari A; Division of Hematopathology, Department of Anatomic and Clinical Pathology, Memorial Healthcare System, Hollywood, FL, USA., Ruiz M; Department of Malignant Hematology and Cellular Therapy at Memorial Healthcare System, H. Lee Moffitt Cancer Center, 801 N Flamingo Road, Pembroke Pines, 33028, FL, USA.
Jazyk: angličtina
Zdroj: International journal of hematology [Int J Hematol] 2019 May; Vol. 109 (5), pp. 622-626. Date of Electronic Publication: 2019 Jan 23.
DOI: 10.1007/s12185-019-02592-3
Abstrakt: Primary effusion lymphoma (PEL) is a rare and aggressive herpesvirus-8 (HHV-8) driven B cell non-Hodgkin's lymphoma (NHL) that is usually associated with human immunodeficiency virus (HIV) infection, and has a poor prognosis. PEL is comprised of two clinically distinct but pathologically similar variants: classic and extracavitary PEL. Based on retrospective series, treatment options include combined antiretroviral therapy (cART) in conjunction with chemotherapy regimens used in other forms of NHLs. Treatment outcomes with this approach are usually dismal and there is no standard of care. We present a case of a patient with HIV associated CD30+ extracavitary PEL unfit for multi-agent chemotherapy, who achieved a durable complete response with single agent brentuximab-vedotin and cART.
Databáze: MEDLINE
Externí odkaz: